Advertisement
Screener

GeneDx Holdings Corp. (WGS) Debt / Equity

GeneDx Holdings Corp. Debt/Equity Ratio

The debt/equity ratio shows how much a company has borrowed for every dollar its shareholders have put in. It is long-term debt, both the part due within a year and the rest, divided by shareholder equity, shown as a multiple with both amounts in the table. A higher ratio means the company relies more on borrowed money than on shareholder capital. Because equity shrinks through buybacks or losses, the ratio can rise even when debt is unchanged, and it has no meaning when equity is negative. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

  • GeneDx Holdings Corp. debt/equity ratio for the quarter ending 2026-06-30 was 0.4, a 107.70% increase year-over-year.
  • GeneDx Holdings Corp. debt/equity ratio for the quarter ending 2026-03-31 was 0.38, a 84.83% increase year-over-year.
  • GeneDx Holdings Corp. debt/equity ratio for the quarter ending 2025-12-31 was 0.17, a 21.03% decline year-over-year.
  • GeneDx Holdings Corp. debt/equity ratio for the quarter ending 2025-09-30 was 0.18, a 30.59% decline year-over-year.
  • GeneDx Holdings Corp. debt/equity ratio for fiscal 2025 was 0.17, a 21.03% decline from fiscal 2024.
  • GeneDx Holdings Corp. debt/equity ratio for fiscal 2024 was 0.22, a 7.13% decline from fiscal 2023.
  • GeneDx Holdings Corp. debt/equity ratio for fiscal 2023 was 0.23, a 437.97% increase from fiscal 2022.
  • GeneDx Holdings Corp. debt/equity ratio for fiscal 2022 was 0.04, a 52.97% increase from fiscal 2021.
Available history
2020-12-31 to 2026-06-30
Data captured

Historical Debt/Equity Ratio

DateDebt/Equity RatioLong-term debtShareholder equity
2026-06-300.4$96.84M$244.22M
2026-03-310.38$96.73M$254.12M
2025-12-310.17$52.72M$308.18M
2025-09-300.18$52.81M$292.26M
2025-06-300.19$52.91M$277.13M
2025-03-310.21$53.01M$257.41M
2024-12-310.22$53.12M$245.25M
2024-09-300.26$53.24M$204.5M
2024-06-300.27$53.26M$194.04M
2024-03-310.26$53.09M$207.22M
2023-12-310.23$53.19M$228.02M
2023-09-300.02$6.25M$254.26M
2023-06-300.02$6.25M$296.11M
2023-03-310.02$6.25M$328.47M
2022-12-310.04$11M$253.71M
2022-09-300.02$11M$561.29M
2022-06-300.02$11M$637.27M
2022-03-310.03$11M$329.44M
2021-12-310.03$11M$388.1M
2021-09-300.03$11M$391.02M
2020-12-31-0.06$20.74M-$330.05M

Annual Debt/Equity Ratio

DateDebt/Equity RatioLong-term debtShareholder equity
2025-12-310.17$52.72M$308.18M
2024-12-310.22$53.12M$245.25M
2023-12-310.23$53.19M$228.02M
2022-12-310.04$11M$253.71M
2021-12-310.03$11M$388.1M
2020-12-31-0.06$20.74M-$330.05M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Privia Health Group, Inc. (PRVA)United States$2.477B115.52
Pennant Group, Inc. (PNTG)United States$1.386B39.84
U S PHYSICAL THERAPY INC /NV (USPH)United States$1.251B32.48
Omada Health, Inc. (OMDA)United States$1.207B309.08
InnovAge Holding Corp. (INNV)United States$1.206B-635.60
LifeStance Health Group, Inc. (LFST)United States$4.510B80.86
Strata Critical Medical, Inc. (SRTA)United States$0.467B11.33
DocGo Inc. (DCGO)United States$0.034B-0.25
VSEE HEALTH, INC. (VSEE)United States$0.003B
Agape ATP Corp (ATPC)$0.002B